Day: July 8, 2025

TAMPA, Fla., July 08, 2025 (GLOBE NEWSWIRE) — SRx Health Solutions, Inc. (NYSE American: SRXH) (“SRX Health” or the “Company”), a leading global health and wellness company, today announced the successful closing of a $7.3 million convertible note financing, led by insiders and existing investors. Additionally, SRX Health has secured a $50 million equity line of credit (‘ELOC’). This financing and ELOC financial commitment significantly strengthens the Company’s balance sheet and provides additional working capital to advance near-term growth initiatives. Lionel Conacher, Chairman of SRx Health Solutions, stated, “These financings represent a pivotal milestone in our transformation into a leading North American healthcare provider. The access to the ELOC allows us optionality to aggressively pursue accretive M&A opportunities...

Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women’s health and family building solutions, today announced that it has entered into a revolving credit facility (the “revolver” or the “facility”) which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expected to enhance the Company’s operational and financial flexibility beyond its current ability to generate significant cash flow. “At this...

RALEIGH, N.C., July 08, 2025 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”), a leading national supplier of aggregates and heavy building materials, today announced the appointment of Michael J. Petro as Senior Vice President and Chief Financial Officer, effective immediately. Robert J. Cardin, who has been serving as the Company’s interim CFO since April 2025, will continue in his role as Senior Vice President, Controller and Chief Accounting Officer. Mr. Petro, who most recently served as Senior Vice President of Strategy and Development at Martin Marietta, brings decades of financial leadership experience. Since joining the Company in 2015, he has played a key role in formulating and executing the Company’s strategic growth initiatives including through his work on successful...

52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs)PHILADELPHIA and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC).BriaCell’s...

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF, FSE: IU3), the Bitcoin Ecosystem Company, is pleased to announce the launch of its Digital Asset Platform today, enabling the creation of unique pieces of digital artwork that can be etched onto 1 gram of physical gold. This innovative platform seamlessly integrates precious metals-based art with blockchain infrastructure, utilizing protocols built on the Bitcoin Network. The launch will take place exclusively on Trio (@trio_xyz), with whitelist access opening at 11am EST and the public release at 12pm EST. For more detailed information and updates, follow us on X at @buymatador. Key Highlights:Grammies – Digital Gold Collectibles: The inaugural product, “Grammies” are digital inscriptions recorded on Bitcoin...

NORWOOD, Mass., July 08, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report second quarter 2025 financial results on August 6, 2025 after the markets close. Management will host a conference call on August 7, 2025 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q2 2025 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website. About MariMedMariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including...

COLUMBUS, Ohio, July 08, 2025 (GLOBE NEWSWIRE) — Bread Financial® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, will host a conference call on Thursday, July 24, 2025, at 8:30 a.m. ET to discuss the company’s second quarter 2025 results. Conference Call/Webcast InformationParticipants can register in advance here, and the conference call will be available at the company’s investor relations website. Analysts planning to participate in the Q&A can register in advance here. Additionally, there will be several slides accompanying the webcast. Please go to the website at least 15 minutes prior to the call to register, as well as download and install any necessary software. The webcast will also be archived on the investor relations...

Substantial clinical need expected to facilitate rapid overall trial enrollment HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the treatment of its initial patients in the Company’s ReSPECT-LM dose optimization trial for REYOBIQTM (rhenium Re186 obisbemeda) for the treatment of leptomeningeal metastases (LM). The dose optimization trial builds on promising results from the Company’s completed Phase 1 single-dose escalation study, which demonstrated the feasibility of REYOBIQ for treating LM. The trial is designed in alignment with the FDA’s Project Optimus to identify the optimal dosing regimen that maximizes...